Dalpiciclib in HR+/HER2- ABC
ConditionAdvanced Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRenJi Hospital
About this trial
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Eligibility criteria
Qualifiers
Histologically confirmed advanced breast cancer
Hormone receptor-positive and human epidermal growth factor receptor 2-negative
ECOG 0-1
Disqualifiers
Pregnant or breastfeeding
History of immunodeficiency
Trial design
Treatments tested in this trial
- dalpiciclib
Treatment groups
103 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov